Co-founder

Dr. Xiaoliang Sunney Xie

Dr. Xiaoliang Sunney Xie is an internationally renowned biophysical chemist. He is a member of the Chinese Academy of Sciences, an elected member of the National Academy of Sciences and National Academy of Medicine, and also a fellow of the American Academy of Arts and Sciences.He had been the Mallinckrodt Professor of Chemistry and Chemical Biology at Harvard University until 2018. He returned to China on that year to continue his distinguished career in scientific research as well as education, and has taken on several fulltime positions since then. He is now the Lee Shau-kee Chair Professor of Peking University, and also the Director of Biomedical Pioneering Innovation Center and Director of Beijing Advanced Innovation Center for Genomics, both at Peking University. 

Immediately after the outbreak of COVID-19, he organized an outstanding multidisciplinary team with members from universities and industries to tackle this critical challenge. His team successfully applied single-cell genomics to the screening of neutralizing antibodies from humans for the first time, and rapidly obtained highly active neutralizing antibodies which are expected to provide a distinctly efficacious treatment for COVID-19.

CEO of Singlomics

Dr. Qian Shi

Prior to joining Singlomics, Dr. Qian Shi was the General Manager and Head of Science of the Chinese arm of Apollomics Inc., bringing to the company his extensive experience in tumor pharmacology and drug discovery. Before this, he worked for more than seven years at Crown Bioscience Inc., as the General Manager of Taicang branch and Vice President of Oncology, directing the Department of in vitro & in vivo Tumor Pharmacology. Prior to this, Dr. Shi had worked as a scientist at ArQule Inc. and a professor as well as principal investigator at Fudan University, Shanghai. His research experience in oncology has spanned for over 20 years. At Apollomics, he led his team in accomplishing the submission of two INDs for the treatment of acute myeloid leukemia and solid tumors, enabling the company to enter clinical stage. He earned his PhD in Oncology and Cancer Biology from the University of Texas MD Anderson Cancer Center, and undertook postdoctoral training at the Dana-Farber Cancer Institute, Harvard Medical School. He has Bachelor's and Master's degrees in Genetics from Fudan University, Shanghai.

Co-founder & Scientific Advisor

Dr. Yunlong Cao

Dr. Yunlong Cao was admitted in a PhD program at the Department of Chemistry and Chemical Biology, Harvard University. Having received his doctorate with distinction, he is now an Associate Professor at the Biomedical Pioneering Innovation Center, Peking University. His research is focused on developing and advancing single-cell sequencing technology. He is the scientific leader of the multidisciplinary team organized by Dr. Xiaoliang Sunney Xie for the research and development of highly active neutralizing antibodies against COVID-19, directing from experimental design to implementation. This work was recently published in a critically acclaimed article in the biological journal, Cell, of which Dr. Cao is the first author. He is also the lead inventor of several critical patents in this field.